Cargando…
The Utility of (1→3)-β-D-Glucan Testing in the Diagnosis of Coccidioidomycosis in Hospitalized Immunocompromised Patients
Coccidioidomycosis is a fungal infection endemic to the Southwestern United States which is associated with high morbidity and mortality in immunocompromised hosts. Serology is the main diagnostic tool, although less sensitive among immunocompromised hosts. (1→3)-β-D-glucan (BDG) is a non-specific f...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9332557/ https://www.ncbi.nlm.nih.gov/pubmed/35893136 http://dx.doi.org/10.3390/jof8080768 |
_version_ | 1784758677294546944 |
---|---|
author | Al-Obaidi, Mohanad M. Ayazi, Parham Shi, Aishan Campanella, Matthew Connick, Elizabeth Zangeneh, Tirdad T. |
author_facet | Al-Obaidi, Mohanad M. Ayazi, Parham Shi, Aishan Campanella, Matthew Connick, Elizabeth Zangeneh, Tirdad T. |
author_sort | Al-Obaidi, Mohanad M. |
collection | PubMed |
description | Coccidioidomycosis is a fungal infection endemic to the Southwestern United States which is associated with high morbidity and mortality in immunocompromised hosts. Serology is the main diagnostic tool, although less sensitive among immunocompromised hosts. (1→3)-β-D-glucan (BDG) is a non-specific fungal diagnostic test that may identify suspected coccidioidomycosis and other invasive fungal infections. We retrospectively investigated the utility of BDG between 2017 and 2021 in immunocompromised hosts with positive Coccidioides spp. cultures at our institutions. During the study period, there were 368 patients with positive cultures for Coccidioides spp.; among those, 28 patients were immunocompromised hosts, had both Coccidioides serology and BDG results available, and met other inclusion and exclusion criteria. Half of the patients had positive Coccidioides serology, and 57% had a positive BDG ≥ 80 pg/mL. Twenty-three (82%) had at least one positive test during their hospitalization. Among immunocompromised hosts with suspicion for coccidioidomycosis, the combination of Coccidioides serology and BDG can be useful in the initial work up and the timely administration of appropriate antifungal therapy. However, both tests failed to diagnose many cases, underscoring the need for better diagnostic techniques for identifying coccidioidomycosis in this population. |
format | Online Article Text |
id | pubmed-9332557 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-93325572022-07-29 The Utility of (1→3)-β-D-Glucan Testing in the Diagnosis of Coccidioidomycosis in Hospitalized Immunocompromised Patients Al-Obaidi, Mohanad M. Ayazi, Parham Shi, Aishan Campanella, Matthew Connick, Elizabeth Zangeneh, Tirdad T. J Fungi (Basel) Brief Report Coccidioidomycosis is a fungal infection endemic to the Southwestern United States which is associated with high morbidity and mortality in immunocompromised hosts. Serology is the main diagnostic tool, although less sensitive among immunocompromised hosts. (1→3)-β-D-glucan (BDG) is a non-specific fungal diagnostic test that may identify suspected coccidioidomycosis and other invasive fungal infections. We retrospectively investigated the utility of BDG between 2017 and 2021 in immunocompromised hosts with positive Coccidioides spp. cultures at our institutions. During the study period, there were 368 patients with positive cultures for Coccidioides spp.; among those, 28 patients were immunocompromised hosts, had both Coccidioides serology and BDG results available, and met other inclusion and exclusion criteria. Half of the patients had positive Coccidioides serology, and 57% had a positive BDG ≥ 80 pg/mL. Twenty-three (82%) had at least one positive test during their hospitalization. Among immunocompromised hosts with suspicion for coccidioidomycosis, the combination of Coccidioides serology and BDG can be useful in the initial work up and the timely administration of appropriate antifungal therapy. However, both tests failed to diagnose many cases, underscoring the need for better diagnostic techniques for identifying coccidioidomycosis in this population. MDPI 2022-07-25 /pmc/articles/PMC9332557/ /pubmed/35893136 http://dx.doi.org/10.3390/jof8080768 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Brief Report Al-Obaidi, Mohanad M. Ayazi, Parham Shi, Aishan Campanella, Matthew Connick, Elizabeth Zangeneh, Tirdad T. The Utility of (1→3)-β-D-Glucan Testing in the Diagnosis of Coccidioidomycosis in Hospitalized Immunocompromised Patients |
title | The Utility of (1→3)-β-D-Glucan Testing in the Diagnosis of Coccidioidomycosis in Hospitalized Immunocompromised Patients |
title_full | The Utility of (1→3)-β-D-Glucan Testing in the Diagnosis of Coccidioidomycosis in Hospitalized Immunocompromised Patients |
title_fullStr | The Utility of (1→3)-β-D-Glucan Testing in the Diagnosis of Coccidioidomycosis in Hospitalized Immunocompromised Patients |
title_full_unstemmed | The Utility of (1→3)-β-D-Glucan Testing in the Diagnosis of Coccidioidomycosis in Hospitalized Immunocompromised Patients |
title_short | The Utility of (1→3)-β-D-Glucan Testing in the Diagnosis of Coccidioidomycosis in Hospitalized Immunocompromised Patients |
title_sort | utility of (1→3)-β-d-glucan testing in the diagnosis of coccidioidomycosis in hospitalized immunocompromised patients |
topic | Brief Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9332557/ https://www.ncbi.nlm.nih.gov/pubmed/35893136 http://dx.doi.org/10.3390/jof8080768 |
work_keys_str_mv | AT alobaidimohanadm theutilityof13bdglucantestinginthediagnosisofcoccidioidomycosisinhospitalizedimmunocompromisedpatients AT ayaziparham theutilityof13bdglucantestinginthediagnosisofcoccidioidomycosisinhospitalizedimmunocompromisedpatients AT shiaishan theutilityof13bdglucantestinginthediagnosisofcoccidioidomycosisinhospitalizedimmunocompromisedpatients AT campanellamatthew theutilityof13bdglucantestinginthediagnosisofcoccidioidomycosisinhospitalizedimmunocompromisedpatients AT connickelizabeth theutilityof13bdglucantestinginthediagnosisofcoccidioidomycosisinhospitalizedimmunocompromisedpatients AT zangenehtirdadt theutilityof13bdglucantestinginthediagnosisofcoccidioidomycosisinhospitalizedimmunocompromisedpatients AT alobaidimohanadm utilityof13bdglucantestinginthediagnosisofcoccidioidomycosisinhospitalizedimmunocompromisedpatients AT ayaziparham utilityof13bdglucantestinginthediagnosisofcoccidioidomycosisinhospitalizedimmunocompromisedpatients AT shiaishan utilityof13bdglucantestinginthediagnosisofcoccidioidomycosisinhospitalizedimmunocompromisedpatients AT campanellamatthew utilityof13bdglucantestinginthediagnosisofcoccidioidomycosisinhospitalizedimmunocompromisedpatients AT connickelizabeth utilityof13bdglucantestinginthediagnosisofcoccidioidomycosisinhospitalizedimmunocompromisedpatients AT zangenehtirdadt utilityof13bdglucantestinginthediagnosisofcoccidioidomycosisinhospitalizedimmunocompromisedpatients |